Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy

Abstract

A benzodiazepine drug, clobazam, was evaluated in 14 refractory epileptic patients, nine of whom received the drug double-blind. Ten patients have been given clobazam long enough to assess results. Four showed marked benefit, four failed to respond and two showed a transient benefit which was maintained by dose changes of both clobazam and clonazepam. Side effects were minimal; doses ranged from 15 to 60 mg per day. Clobazam may have place in the treatment of the Lennox Gastaut syndrome and other types of refractory seizures.